Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies Clinical Trial

Official title:

A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04521413
• Other study ID #: TWT-101
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: August 31, 2020
• Est. completion date: December 2024

Study information

• Verified date: April 2024
• Source: Treadwell Therapeutics, Inc
• Contact: Treadwell Therapeutics Clinical Trials
• Phone: +1-416-455-7510
• Email: clinicaltrials[@]treadwelltx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.

Description:

This study will be a first-in-human study evaluating the safety and tolerability of CFI-402411 in subjects with advanced solid malignancies, when CFI-402411 is administered as a single agent or in combination with pembrolizumab. CFI-402411 is an oral pill that blocks the function of HPK1. Blocking HPK1 could stimulate an immune response against the tumor in patients. This immune response could be further enhanced when combined with pembrolizumab. The data obtained from this study will determine the dose and schedule and subject selection for further clinical studies.

Pre-clinical findings support further development of CFI-402411 as a novel anti-cancer agent, and the combination of CFI-402411 with pembrolizumab as a potential strategy to improve outcomes of subjects with advanced malignancies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: December 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria: Study-Wide Eligibility (Across All Study Parts):

1. Age > 18 years old

2. Have progressed after = 1, but no more than 3 regimens of systemic therapies for recurrent / metastatic disease.

3. Subjects must have measurable disease.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Part A1: Monotherapy Dose Escalation Inclusion Criteria

1. Histological or cytological confirmation of advanced solid malignancy that is refractory to or not a candidate for current standard treatment(s) and for whom no standard therapy is available.

Part A2: Biomarker-Focused Monotherapy Backfills Inclusion Criteria

1. Histological or cytological confirmation of one of the advanced cancers listed below;

• NSCLC

• SCLC

• cutaneous melanoma

• Merkel cell carcinoma

• squamous cell carcinoma of head and neck, anal canal, or skin

• urothelial cancer

• clear cell or non-clear cell renal cell carcinoma

• triple negative breast cancer

• endometrial cancer (regardless of MSI status)

• cervical cancer

• gastroesophageal cancer

• hepatocellular cancer

• any histology if known to be microsatellite-instability high (MSI-H)

2. Tumors must be refractory to or not a candidate for current standard treatment(s) and for whom no standard therapy exists.

Part A3: Monotherapy Expansion Inclusion Criteria

1. Histological or cytological confirmation of one of the advanced cancers listed below;

• NSCLC cancer any histology

• SCLC

• cutaneous melanoma

• Merkel cell carcinoma

• squamous cell carcinoma of head and neck, anal canal, or skin

• urothelial cancer

• clear cell or non-clear cell renal cell carcinoma

• triple negative breast cancer

• endometrial cancer (regardless of MSI status)

• cervical cancer

• gastroesophageal cancer

• hepatocellular

• any histology if known to be microsatellite-instability high (MSI-H)

2. Tumors must be refractory to or subjects intolerant of current standard treatment(s) and for whom no standard therapies are available.

3. Optional biopsies: Subjects that consent to optional fresh tumor biopsies must have at least one non-target soft tissue tumor lesion that can be biopsied.

Part B1: CFI-402411 in Combination with Pembrolizumab Dose Escalation Inclusion Criteria

1. Subjects must be deemed eligible by the Investigator to receive pembrolizumab.

2. Histological or cytological confirmation of one of the advanced cancers listed below (list may vary in each country, USA shown here);

• NSCLC cancer any histology

• SCLC

• cutaneous melanoma

• Merkel cell carcinoma

• squamous cell carcinoma of head and neck, anal canal, or skin

• urothelial cancer

• clear cell or non-clear cell renal cell carcinoma

• triple negative breast cancer

• endometrial cancer (regardless of MSI status)

• cervical cancer

• gastroesophageal cancer

• hepatocellular cancer

• any histology if known to be microsatellite-instability high (MSI-H)

Tumors must be refractory to or subjects intolerant of current standard treatment(s) or for whom no standard therapy is available.

Part B2: CFI-402411 in Combination with Pembrolizumab Expansion Inclusion Criteria

1. Subjects must be deemed eligible by the Investigator to receive pembrolizumab

2. Histological or cytological confirmation of one of the advanced cancers listed below (list may vary in each country, USA shown here);

• non-small cell lung cancer any histology

• SCLC

• cutaneous melanoma

• Merkel Cell carcinoma

• squamous cell carcinoma of head and neck, anal canal, or skin

• urothelial cancer

• clear cell or non-clear cell renal cell carcinoma

• triple negative breast cancer

• endometrial cancer (regardless of MSI status)

• gastroesophageal cancer

• hepatocellular cancer

• any histology if known to be microsatellite-instability high (MSI-H)

3. Tumors must be refractory to or subjects intolerant of current standard non-IO treatment(s) or for whom no standard therapy is available.

Key Exclusion Criteria: Study-Wide Eligibility (Across All Study Parts)

Subjects will be excluded from the study if any of the following criteria is met;

1. Previous treatment with an HPK1 inhibitor in other clinical trials.

2. Diagnosis of autoimmune-based disease or clinically significant auto-immune disorders.

3. Have symptomatic congestive heart failure, active angina pectoris or recent myocardial infarction (within 6 mos).

4. Have chronic atrial fibrillation.

5. Known central nervous system metastasis.

6. Stroke or transient ischemic attack, or other ischemic events or thromboembolic events within 3 months of study enrollment.

7. A history of QTc prolongation or a marked baseline prolongation of QT/QTc interval or a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).

Related Conditions & MeSH terms

• Advanced Solid Malignancies
• Neoplasms

Intervention

Drug:
• CFI-402411
CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
• Pembrolizumab
Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	The Ottawa Hospital	Ottawa	Ontario
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Hong Kong	Prince of Wales Hospital	Sha Tin
United States	Virginia Cancer Specialist	Fairfax	Virginia
United States	START - Mid-West	Grand Rapids	Michigan
United States	MD Anderson	Houston	Texas
United States	University of California San Diego	La Jolla	California
United States	The Angeles Clinic	Los Angeles	California
United States	SCRI - Nashville	Nashville	Tennessee
United States	Yale Cancer Center	New Haven	Connecticut
United States	START - San Antonio	San Antonio	Texas
United States	Florida Cancer Specialists	Sarasota	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Treadwell Therapeutics, Inc	TIO Discovery Engine

Countries where clinical trial is conducted

United States,  Canada,  Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the incidence of adverse events of CFI-402411 as a single agent and at the recommended phase 2 dose (RP2D).	The number of subjects who experience an adverse event that was possibly related to study drug.	48 months
Primary	To assess the incidence of adverse events with CFI-402411 in combination with pembrolizumab and at the RP2D.	The number of subjects who experience an adverse event that was possibly related to study drug.	48 months
Primary	To examine best overall response rate in subjects treated at multiple dose levels of CFI-402411.	Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.	48 months
Primary	To examine progression free survival in subjects treated at multiple dose levels of CFI-402411.	Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.	48 months
Secondary	To identify the maximum tolerated dose of single agent CFI-402411 alone and in combination with pembrolizumab.	Safety tables and pharmacokinetic tables will be assessed.	48 months
Secondary	To further assess the incidence of adverse events of CFI-402411.	The number of subjects who experience an adverse event that was possibly related to study drug.	48 months
Secondary	To assess best overall response of CFI-402411 monotherapy and in combination with pembrolizumab.	Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.	48 months
Secondary	To assess overall response rates of CFI-402411 monotherapy and in combination with pembrolizumab.	For all subjects the overall response rates of complete response and partial response will be calculated and summarized by dose cohort and overall.	48 months
Secondary	To assess overall survival of CFI-402411 monotherapy and in combination with pembrolizumab.	The time from first dose until the date of death from any cause will be calculated and summarized for all patients by dose cohort and overall.	48 months
Secondary	To assess progression free survival of CFI-402411 monotherapy and in combination with pembrolizumab.	Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.	48 months
Secondary	To assess duration of response of CFI-402411 monotherapy and in combination with pembrolizumab.	The time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurs first, will be calculated and summarized for all patients by dose cohort and overall.	48 months
Secondary	To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through AUC.	Area under the plasma concentration (AUC) versus time curve from time 0 to time of least measurable concentration tabulated by dose group.	48 months
Secondary	To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Cmax.	Cmax will be assessed through the maximum measured plasma concentration occurring at Tmax tabulated by dose group.	48 months
Secondary	To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Tmax.	Tmax will be assessed by the time to achieve maximum plasma concentration and will be tabulated by dose group.	48 months
Secondary	To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab though Cmin.	Cmin will be calculated through the measured pre-dose plasma concentration and tabulated by dose group.	48 months
Secondary	To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through T1/2.	Elimination half life will be calculated and tabulated by dose group.	48 months
Secondary	To evaluate the effect of CFI-402411 treatment on immune- or disease related biomarkers.	The effects of CFI-402411 on pharmacodynamic biomarkers (cytokine levels) will be assessed by percent changes from baseline.	48 months